Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

patient population includes a wide range of patients with a broad clinical profile," said Leonard Bell, MD, Chief Executive Officer of Alexion Pharmaceuticals. "The results presented today provide further evidence for the utility of Soliris therapy in patients with diverse manifestations of PNH. We remain committed to our goal that all patients who can benefit from Soliris will have access to it."

Soliris, developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), is the first therapy approved for the treatment of patients with PNH, a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. Soliris is a complement inhibitor indicated for the treatment of patients with PNH to reduce hemolysis. In patients with PNH, hemolysis can cause thromboses, kidney disease, liver dysfunction, disabling fatigue, impaired quality of life, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), and anemia. (2-4)

Clinical Data

In the ongoing open-label clinical study, investigators examined the long- term clinical effect of Soliris in patient subgroups, including those with lower levels of hemolysis, mild anemia and minimal transfusion requirements.

Data were analyzed by levels of baseline hemolysis (as indicated by baseline quartiles of lactate dehydrogenase, LDH), anemia (Hgb < 10.5 g/L vs greater than or equal to 10.5 g/L), and transfusion requirements (transfusion episodes in prior year greater than 1 vs 1 or 0 episodes). Hemolysis, fatigue and transfusion requirements were examined using a ranking test to measure efficacy during both the first and the most recent six months of Soliris therapy; patients rec
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Jan. 27, 2012 Neurodevice firm ... Series B investment round led by ... 2011, and secured non-dilutive funding of ... million Innovation Ohio loan and a ...
... GAITHERSBURG, Md., Jan. 27, 2012 GenVec, Inc. (Nasdaq: ... proprietary technologies to create superior therapeutics and vaccines, today ... License Agreement with Novartis (NYSE: NVS).  Under the extension, ... to support its hearing loss and balance disorders program. ...
Cached Medicine Technology:Neurodevice Firm Checkpoint Surgical Raises $3M 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 3
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
(Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3
... its spa/gourmet green tea at the Las Vegas IECSC, ... the,International Esthetics, Cosmetics & Spa Conference (IECSC) in Las ... will feature one,product unique for its simplicity: green tea. ... Shinwa, an all-natural, organic,green Japanese karigane tea, at the ...
... - SXC Health Solutions, Corp.,("SXC" or the "Company") ... provider of,technology and pharmacy benefits management services, announces ... awarded a,three-year $35 million Pharmacy Benefits Manager (PBM) ... ("TennCare")., Under terms of the proposed agreement, ...
... 23 , - Special Library Association (SLA) ... Anniversary of SLA and Honor Two,Lifetimes of Achievement, ... John,and Jean Piety on being this year,s recipients ... of the Year Award. Mr.,and Mrs. Piety,s contributions ...
... MONDAY JUNE 23, 2008 , LOW SOCIOECONOMIC STATUS INCREASES ... with low socioeconomic status (SES) have more advanced cancers at ... of dying in the five years following cancer diagnosis, according ... the August 1, 2008 issue of CANCER , a ...
... women are struggling with the health fallout caused by a ... -- Most women don,t need a survey to tell them ... feel too sluggish to make it through the day with ... single moms, empty-nesters or grandmothers, many -- if not most ...
... (formerly,Diagnostic Ultrasound Corp.), the maker of BladderScan(R) bladder ... selection, for the second year in a row, ... in Washington State by Washington CEO Magazine., ... as the 4th "Best Company To Work For" ...
Cached Medicine News:Health News:Health and Beauty Come Full Circle: Chado-En Brings Full Benefit of Japanese Green Tea to Spas 2Health News:SXC Health Solutions announces three-year $35 million PBM contract with the State of Tennessee 2Health News:John & Jean Piety Named SLA Engineering Librarians of the Year 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 3Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 4Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 5Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Verathon Inc., Recognized, Second Year Running, as Outstanding Workplace in Washington State by Washington CEO Magazine 2
... unique thread design is the ultimate anchor ... to pull out, proven delivery, two sutures ... This provides the orthopedic surgeon a superior ... , ,The TwinFix AB anchor was developed ...
... ConTack Labral Anchor is an L-PLA ... for soft tissue reattachment to bone. ... the bony contour of the glenoid, ... Radial Osteo Compression (ROC) design to ...
... can be used for open or arthroscopic ... a sterile disposable inserter. The unique deployment ... insertion of the anchor into bone. ... allows for the two pre-threaded sutures to ...
... TACIT Threaded Anchor and ... in craniofacial and hand ... secure tissue reattachment and ... The small size facilitates ...
Medicine Products: